A new study examining real-world hospital data reveals early indicators of who is most likely to benefit from Cobenfy, the first new schizophrenia drug mechanism approved in 50 years.

Schizophrenia, a psychiatric disorder that affects how a person feels, thinks, and behaves, affects roughly 1% of the ...

An update from Luye Pharma Group ( ($HK:2186) ) is now available. Luye Pharma Group Ltd. has received FDA clearance to initiate clinical trials in ...

Scientists have discovered a surprising benefit of the acne drug doxycycline: it may lower the risk of schizophrenia. Teens prescribed the antibiotic were about one-third less likely to develop the ...

Taking acne drug doxycycline has been linked to a lower risk of schizophrenia, reported a new study published in the American ...

Sun Pharmaceutical issued a voluntary recall of lisdexamfetamine dimesylate capsules, used for attention deficit-hyperactivity disorder (ADHD), after failing dissolution tests, the FDA said.

They are more likely to die from disease. They are more likely to die from violence. They are more likely to die as they age. And they don’t live nearly as long. The life expectancy of people with ...

Cognision, provider of advanced neurobiomarker technology, announces its partnership with Kynexis to utilize the COGNISION(R) System in Kynexis' Phase 2 clinical trial of KYN-5356 in subjects with ...

Cognision, provider of advanced neurobiomarker technology, announces its partnership with Kynexis to utilize the COGNISION® System in Kynexis' Phase 2 clinical trial of KYN-5356 in subjects with ...

Data from the SERENITY At-Home Phase 3 trial were presented on November 7 at the 2025 Neuroscience Education Institute Fall Congress by Dr. Leslie Citrome.

Teens prescribed the common antibiotic doxycycline were found to have a much lower risk of developing schizophrenia as adults.

Another of the psychiatry drugs Neurocrine Biosciences licensed from Takeda has stumbled in the clinic. | Another of the ...